Feasibility of Salvage Re-irradiation With Stereotactic Radiotherapy for Recurrent Glioma Using CyberKnife

To evaluate the toxicity and efficacy of re-irradiation with salvage stereotactic radiotherapy (SRT) for recurrent glioma using CyberKnife. This study retrospectively investigated 35 patients with 48 recurrent grade 2-4 gliomas who received SRT between 1998 and 2011. Six patients (17.1%) had grade 2...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-06, Vol.39 (6), p.2935-2940
Main Authors: Adachi, Kana, Hayashi, Kazuhiko, Kagawa, Naoki, Kinoshita, Manabu, Sumida, Iori, Akino, Yuichi, Shiomi, Hiroya, Tamari, Keisuke, Suzuki, Osamu, Hirayama, Ryuichi, Kijima, Noriyuki, Isohashi, Fumiaki, Seo, Yuji, Otani, Keisuke, Kishima, Haruhiko, Ogawa, Kazuhiko
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Brain
Brain Neoplasms - radiotherapy
Child
Feasibility
Feasibility Studies
Female
Glioma
Glioma - radiotherapy
Humans
Irradiation
Male
Middle Aged
Necrosis
Neoplasm Recurrence, Local - radiotherapy
Prognosis
Radiation
Radiation Dosage
Radiation effects
Radiation therapy
Radiosurgery - adverse effects
Retrospective Studies
Salvage
Salvage Therapy - adverse effects
Surgery
Survival
Toxicity
Treatment Outcome
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the toxicity and efficacy of re-irradiation with salvage stereotactic radiotherapy (SRT) for recurrent glioma using CyberKnife. This study retrospectively investigated 35 patients with 48 recurrent grade 2-4 gliomas who received SRT between 1998 and 2011. Six patients (17.1%) had grade 2 gliomas, nine (25.7%) had grade 3 gliomas, and 20 (57.1%) had glioblastomas; all initially underwent surgery and conventional radiotherapy. The median initial and subsequent radiotherapy doses were 60 and 26 Gy, respectively. After a median follow-up period of 9.0 months, the only toxicity of grade 2 or more was radiation-induced brain necrosis in four patients (11.4%). The median overall and progression-free survival periods following re-irradiation were 9.0 and 3.0 months, respectively. Univariate analysis revealed that performance status at salvage re-irradiation was a significant predictor of progression-free survival. Salvage re-irradiation using CyberKnife is feasible, with an acceptable toxicity profile, for patients with recurrent glioma.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13423